glp 1 m GLP-1 receptor biology: structure, signaling, and distribution 1 medications or looking for a natural alternative. GLP-1 Weight Loss Drugs May

Mortality and serious adverse events associated with glucagon-like peptide-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system

NNMT is overexpressed in adipose tissue of obese subjects, and its inhibition has been explored as a strategy to modulate methyl group flux and NAD+ precursor availability

Reduces Age-Related Metabolic Decline MOTS-C levels naturally decline with age, contributing to metabolic dysfunction in older adults

Small lentiginous junctional melanocytic nevi may have only very few nests

Download the Notable Articles of 2025: nej.md/3L4ot87 In the phase 3 ACHIEVE-1 trial, published in June 2025, the oral small-molecule GLP-1 receptor agonist orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with early type 2 diabetes

For instance, in the DURATION-8 trial [36], once-weekly exenatide in combination with once-daily dapagliflozin did not lead to major hypoglycemia episodes over 104 weeks of treatment, with few events of minor hypoglycemia (1.7%)